Bittoo  Kanwar net worth and biography

Bittoo Kanwar Biography and Net Worth

Bittoo leads Clinical Development activities at Applied Molecular Transport, where he is overseeing the current clinical program AMT-101 and developing clinical strategy for the company’s pipeline assets and technology platforms. Previously, Bittoo was VP of Clinical Development at Protagonist Therapeutics where he led programs in Ulcerative Colitis and Crohn’s Disease. He began his industry career at Gilead Sciences where he supported programs in liver fibrosis/NASH, Hepatitis B and C, and served as the Clinical Domain Lead for Inflammatory Bowel Disease. Prior to his career in industry, Bittoo was an adjunct associate professor at UCSF focused on researching the role of the gut adaptive immune response in both HIV infection and IBD. Bittoo obtained his MD from the University of Iowa, completed his residency at Rush University Hospitals in Chicago, and a fellowship in pediatric gastroenterology from UCSF.

What is Bittoo Kanwar's net worth?

The estimated net worth of Bittoo Kanwar is at least $1,972.50 as of April 7th, 2021. Kanwar owns 7,500 shares of Applied Molecular Transport stock worth more than $1,973 as of March 28th. This net worth estimate does not reflect any other investments that Kanwar may own. Learn More about Bittoo Kanwar's net worth.

How do I contact Bittoo Kanwar?

The corporate mailing address for Kanwar and other Applied Molecular Transport executives is 1 TOWER PLACE SUITE 850, SOUTH SAN FRANCISCO CA, 94080. Applied Molecular Transport can also be reached via phone at 650-392-0420 and via email at [email protected]. Learn More on Bittoo Kanwar's contact information.

Has Bittoo Kanwar been buying or selling shares of Applied Molecular Transport?

Bittoo Kanwar has not been actively trading shares of Applied Molecular Transport during the last quarter. Most recently, Bittoo Kanwar sold 7,500 shares of the business's stock in a transaction on Wednesday, July 7th. The shares were sold at an average price of $42.09, for a transaction totalling $315,675.00. Learn More on Bittoo Kanwar's trading history.

Who are Applied Molecular Transport's active insiders?

Applied Molecular Transport's insider roster includes Elizabeth Bhatt (Insider), Shawn Cross (CFO), Bittoo Kanwar (Insider), Helen Kim (Director), David Lamond (Director), Tahir Mahmood (CEO), Randall Mrsny (Insider), and Aaron VanDevender (Director). Learn More on Applied Molecular Transport's active insiders.

Are insiders buying or selling shares of Applied Molecular Transport?

During the last twelve months, insiders at the sold shares 14 times. They sold a total of 1,097,868 shares worth more than $176,549.76. The most recent insider tranaction occured on November, 22nd when CEO Shawn Cross sold 110,802 shares worth more than $17,728.32. Insiders at Applied Molecular Transport own 15.9% of the company. Learn More about insider trades at Applied Molecular Transport.

Information on this page was last updated on 11/22/2023.

Bittoo Kanwar Insider Trading History at Applied Molecular Transport

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/7/2021Sell7,500$42.09$315,675.00View SEC Filing Icon  
4/7/2021Sell7,500$54.79$410,925.007,500View SEC Filing Icon  
See Full Table

Bittoo Kanwar Buying and Selling Activity at Applied Molecular Transport

This chart shows Bittoo Kanwar's buying and selling at Applied Molecular Transport by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Applied Molecular Transport Company Overview

Applied Molecular Transport logo
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California. As of December 27, 2023, Applied Molecular Transport Inc. operates as a subsidiary of Cyclo Therapeutics, Inc.
Read More

Today's Range

Now: $0.26
Low: $0.26
High: $0.26

50 Day Range

MA: $0.24
Low: $0.16
High: $0.31

2 Week Range

Now: $0.26
Low: $0.13
High: $0.84

Volume

N/A

Average Volume

470,969 shs

Market Capitalization

$10.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.28